uniQure N.V (UQ1) - Total Liabilities
Based on the latest financial reports, uniQure N.V (UQ1) has total liabilities worth €659.64 Million EUR (≈ $771.18 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore UQ1 cash generation efficiency to assess how effectively this company generates cash.
uniQure N.V - Total Liabilities Trend (2016–2024)
This chart illustrates how uniQure N.V's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of uniQure N.V to evaluate the company's liquid asset resilience ratio.
uniQure N.V Competitors by Total Liabilities
The table below lists competitors of uniQure N.V ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IRSA Inversiones y Representaciones SA
BA:IRSA
|
Argentina | AR$2.22 Trillion |
|
Red Cat Holdings Inc
NASDAQ:RCAT
|
USA | $31.77 Million |
|
CVR Partners LP
NYSE:UAN
|
USA | $703.71 Million |
|
SkiStar AB (publ)
ST:SKIS-B
|
Sweden | Skr5.60 Billion |
|
HUANLEJIA Food Group Co. Ltd.
SHE:300997
|
China | CN¥707.74 Million |
|
RPC Inc
NYSE:RES
|
USA | $369.21 Million |
|
Hengdian Group Tospo Lighting Co Ltd
SHG:603303
|
China | CN¥2.58 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down uniQure N.V's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of uniQure N.V.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how uniQure N.V's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for uniQure N.V (2016–2024)
The table below shows the annual total liabilities of uniQure N.V from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €563.29 Million ≈ $658.54 Million |
-9.73% |
| 2023-12-31 | €624.02 Million ≈ $729.54 Million |
+172.55% |
| 2022-12-31 | €228.96 Million ≈ $267.67 Million |
+7.29% |
| 2021-12-31 | €213.40 Million ≈ $249.49 Million |
+121.17% |
| 2020-12-31 | €96.49 Million ≈ $112.81 Million |
-23.16% |
| 2019-12-31 | €125.57 Million ≈ $146.81 Million |
+33.16% |
| 2018-12-31 | €94.30 Million ≈ $110.25 Million |
-21.60% |
| 2017-12-31 | €120.28 Million ≈ $140.63 Million |
-5.01% |
| 2016-12-31 | €126.63 Million ≈ $148.05 Million |
-- |
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more